Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunitybio Inc (IBRX)

Immunitybio Inc (IBRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,338,431
  • Shares Outstanding, K 853,442
  • Annual Sales, $ 14,750 K
  • Annual Income, $ -413,560 K
  • EBIT $ -344 M
  • EBITDA $ -306 M
  • 60-Month Beta 0.82
  • Price/Sales 164.96
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 114.59% ( +3.15%)
  • Historical Volatility 95.43%
  • IV Percentile 63%
  • IV Rank 25.15%
  • IV High 416.96% on 04/25/24
  • IV Low 12.98% on 09/10/24
  • Put/Call Vol Ratio 0.18
  • Today's Volume 1,862
  • Volume Avg (30-Day) 3,681
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 168,595
  • Open Int (30-Day) 185,594

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.11
  • Low Estimate -0.12
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.68 +3.73%
on 03/21/25
3.51 -20.80%
on 02/28/25
-0.22 (-7.33%)
since 02/26/25
3-Month
2.28 +21.93%
on 01/14/25
4.27 -34.89%
on 02/19/25
+0.09 (+3.35%)
since 12/26/24
52-Week
2.28 +21.93%
on 01/14/25
10.53 -73.60%
on 04/29/24
-2.34 (-45.70%)
since 03/26/24

Most Recent Stories

More News
ImmunityBio: Q4 Earnings Snapshot

ImmunityBio: Q4 Earnings Snapshot

IBRX : 2.78 (+1.46%)
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies

The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.

MRK : 88.11 (+0.27%)
IBRX : 2.78 (+1.46%)
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins

Vancouver, BC – February 18, 2025 – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers), there is still cause...

ONCY : 0.6233 (-1.80%)
ALLO : 1.5700 (-1.87%)
VRCA : 0.4445 (-6.75%)
ONC.TO : 0.90 (-1.10%)
OSTX : 1.6300 (+2.52%)
IBRX : 2.78 (+1.46%)
Optimism in War on Cancer on the Rise, as Biotech Companies Roll Out More Wins

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI data centers),...

ALLO : 1.5700 (-1.87%)
ONCY : 0.6233 (-1.80%)
VRCA : 0.4445 (-6.75%)
ONC.TO : 0.90 (-1.10%)
IBRX : 2.78 (+1.46%)
OSTX : 1.6300 (+2.52%)
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism

The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer

ONC : 250.92 (+0.18%)
IBRX : 2.78 (+1.46%)
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Immunotherapy is revolutionizing oncology by harnessing the power of the immune system to fight cancer...

ONCY : 0.6233 (-1.80%)
AUTL : 1.6300 (+0.62%)
IOVA : 3.44 (-1.15%)
ABBV : 201.30 (-0.02%)
ONC.TO : 0.90 (-1.10%)
IBRX : 2.78 (+1.46%)
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll...

ONCY : 0.6233 (-1.80%)
IOVA : 3.44 (-1.15%)
SNDX : 13.13 (-2.31%)
ONC.TO : 0.90 (-1.10%)
IBRX : 2.78 (+1.46%)
SWTX : 46.48 (-1.55%)
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

/CNW/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American...

ONCY : 0.6233 (-1.80%)
IOVA : 3.44 (-1.15%)
SNDX : 13.13 (-2.31%)
ONC.TO : 0.90 (-1.10%)
IBRX : 2.78 (+1.46%)
SWTX : 46.48 (-1.55%)
ImmunityBio: Q3 Earnings Snapshot

ImmunityBio: Q3 Earnings Snapshot

IBRX : 2.78 (+1.46%)
Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider

Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – Back in 2022, Nature published...

BIOV.CN : 0.0500 (-9.09%)
BVAXF : 0.0400 (+5.54%)
BNTX : 95.90 (-1.18%)
CVAC : 2.85 (-2.06%)
VXRT : 0.4645 (-3.45%)
IBRX : 2.78 (+1.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

ImmunityBio Inc. is a late-clinical-stage immunotherapy company developing therapies which drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems. ImmunityBio Inc., formerly known as NantKwest...

See More

Key Turning Points

3rd Resistance Point 2.91
2nd Resistance Point 2.85
1st Resistance Point 2.82
Last Price 2.78
1st Support Level 2.73
2nd Support Level 2.67
3rd Support Level 2.64

See More

52-Week High 10.53
Fibonacci 61.8% 7.38
Fibonacci 50% 6.40
Fibonacci 38.2% 5.43
Last Price 2.78
52-Week Low 2.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar